Deep CariesNCT03186690
Similar Outcomes of Vital Pulp Therapy Using Mineral Trioxide Aggregate or Biodentine™
A study testing Biodentine and Mineral Trioxide Aggregate in people with Deep Caries and Reversible Pulpitis, run by Jordan University of Science and Technology at 1 site in Jordan.
Trial summary
This study aimed to evaluate the clinical performance of White MTA (MTA, Angelus, Londrina, Brazil) and Biodentine™ in pulp capping of cariously exposed mature permanent teeth. The investigator performed a prospective longitudinal randomized controlled study utilizing vital permanent mature teeth with deep caries. Read more about this study
- Who is it for?
- Ages 16 years and olderHealthy volunteers can take part
- Conditions the study is for
- Deep Caries, Reversible Pulpitis, Irreversible Pulpitis
- What is being tested?
- Biodentine and Mineral Trioxide Aggregate
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteJordan
- Study dates
- 4 Jul 2013to 4 Oct 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 16 years and older
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Who may be able to join
- Teeth that Fulfilled All the Following Criteria Were Selected
- Vital teeth responding positively to cold test.
- Reversible or irreversible pulpitis with or without periapical lesion.
- Deep caries that if removed exposure of the pulp is most likely to occur.
- Permanent mature molar, premolar or anterior tooth
- The tooth should be restorable.
- No serious medical problem that could prevent the patient from receiving the treatment or attending later the follow up visits.
Who cannot join
- Immature tooth
- Unrestorable tooth
- Tooth that did not respond to cold test
- Serious medical problem that could prevent the patient from receiving the treatment or attending later the follow up visits.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: 154/2013 Grant for Mineral Trioxide Aggregate and Biodentine for Vital Pulp Therapy
This study aimed to evaluate the clinical performance of White MTA (MTA, Angelus, Londrina, Brazil) and Biodentine™ in pulp capping of cariously exposed mature permanent teeth.
The investigator performed a prospective longitudinal randomized controlled study utilizing vital permanent mature teeth with deep caries. Patients will be divided randomly into Biodentine™ and MTA groups; Teeth will be assessed clinically and radiographically prior to the procedure. Caries will be excavated under local anesthesia, hemostasis is achieved after pulp exposure using NaOCl and will be capped with Biodentine™ or MTA. Clinical and radiographical follow-up will be performed by a blinded calibrated evaluator after six months and one year, and yearly after.
Read the detailed description
Study design and ethical approval This prospective longitudinal, parallel-design, randomized clinical trial was set up and is reported according to CONSORT statement. It assessed the outcome of using Biodentine or MTA as a capping material in human mature permanent teeth. Ethical approval for this study was obtained from the Institution Review Board (IRB number (154/13). All participants provided written informed consent after the purpose and methodology were explained in full.
Patient recruitment All patients visiting the Initial Treatment Unit and Post Graduate Dental Clinics were screened for inclusion . Dental examinations were performed to determine whether the patients fulfilled the needed criteria
Approximately 50 subjects will be needed for the study in order to elicit any significant findings as demonstrated by a power analysis from a similar study. The patients will be divided into two groups based on the capping material used. Biodentine™ (Septodont, St. Maur-des-Fossés, France) group, and MTA reparative cement (Angelus, Londrina, Brazil) group. Teeth will be randomly assigned to either group with a coin toss. This included patients with a single offending tooth; the following patient will be then assigned to the other group to keep sample sizes equal in both groups. Patients with more than one offending tooth will have one tooth treated with Biodentine and the other with MTA using again coin toss to randomly distribute capping material among offending teeth.
Clinical examination Pre-operative clinical examinations included a visual inspection of the extent of caries, gingival health, and adjacent soft tissue. A percussion test will be performed, and the periodontal status will be assessed. Pulpal sensibility will also be assessed by cold test with Endo Ice F (Colten-Whaledent, Germany). Patients reporting sharp pain to cold test that did not linger were diagnosed with reversible pulpitis. Patients reporting severe lingering or spontaneous pain were diagnosed with irreversible pulpitis.
Periapical and bitewing radiographs will be obtained for each offending tooth to assess the extent and location of caries, proximity of caries to the pulp, restorability of each tooth, periapical status, and presence of intra-radicular pathosis. Radiographs will be taken using a parallel technique and will be viewed by the naked eye using a viewing box with uniform bright light in a darkened room. All data will be collected by one examiner to ensure reliability.
Clinical protocol Profound local anesthesia of each tooth will achieved by standard infiltration or inferior dental block injection with lidocaine and epinephrine (1:100000) (Xylestesin-A 3M ESPE, Seefeld, Germany). Then, the tooth will be isolated with a rubber dam. The clinical crown disinfected with a cotton pellet soaked in chlorhexidine. Caries will be excavated using a round, high-speed diamond bur with adequate water cooling followed by a round carbide bur. Every attempt will be carried to remove all carious tissue before exposing the pulp. A cotton pellet moistened with 5% NaOCl to be placed into the cavity before pulpal exposure. The size of the pellet varied according to the size of remaining caries; The moistened cotton pellet was left in place for 1-5 minutes to achieve hemostasis. Sodium hypochlorite-soaked cotton will be used to control bleeding in this study.
Once bleeding stopped, capping material will be placed over the exposed pulp. Failure to stop bleeding within additional 3 minutes indicated incomplete removal of the inflamed pulp. In these cases, partial or complete pulpotomy will be performed before capping. Failure to control bleeding after a full pulpotomy indicated propagation of the inflammation to the radicular pulp.
Biodentine™ will be prepared according to the manufacturer's instructions and used to fill half the cavity. Biodentine™ should set within 12 minutes according to the manufacturer. MTA reparative cement will be prepared at a powder:liquid ratio of 3:1 using distilled water according to manufacturer's instructions . MTA to be applied to exposed pulp tissue and adjacent dentine at a thickness of 1.5 to 3 mm. The final restoration will be a resin composite (Z250, 3M, ESPE, USA). Patients are asked to contact the operator if they experience any pain. The first review appointment to be scheduled a week after capping procedure. The patient will be questioned about sensitivity, mastication discomfort, and sensations of pain.
Recall protocol Six-month and yearly after follow-up appointments will be scheduled. Patients, who are not aware of the type of capping material received, will be questioned about pain, sensitivity, and mastication discomfort. Clinical examinations to be performed to detect soft tissue swelling, sinus tract, the integrity of the coronal restoration, and tooth mobility. The review visits to be performed blindly by another operator. Radiographical examinations will also be performed to evaluate the periapical status, the formation of the dentine bridge, pulpal calcifications, or canal obliteration and evidence of tooth discoloration. Tooth vitality will be monitored by cold tests. Treatment was considered successful based on the following features: absence of severe spontaneous pain, no discomfort while eating, no soft tissue swelling, mobility that is no greater than grade I, the absence of periapical rarefaction, internal or external resorption, root canal obliteration, and normal viability following pulpotomy.
Statistical analysis The data will be processed using the JMP software (SAS Institute Inc., North Carolina, United States) with alpha=0.05. The chi-square test (significance level of < 0.05) will be used to determine differences between the success rates of Biodentine and MTA. The survival probabilities will be compared using The Wilcoxon and the log-rank tests.
- Conditions
- Deep Caries, Reversible Pulpitis, Irreversible Pulpitis
- Being tested
- Biodentine, Mineral Trioxide Aggregate
- Keywords
- vital pulp therapy, Biodentine, Mineral Trioxide Aggregate
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
BiodentineOther
Mineral Trioxide AggregateOther
Also called MTA
| Study group | Role | What they receive |
|---|---|---|
| Biodentine | Experimental | This includes teeth that were treated with Biodntine cement Receives: Other: Biodentine |
| Mineral Trioxide Aggregate | Experimental | This includes teeth that were treated with Mineral Trioxide Aggregate (MTA) cement Receives: Other: Mineral Trioxide Aggregate |
What is being measured
The primary outcome is the main question the study is designed to answer.
clinical vital pulp therapy success
Treatment was considered successful based on absence of symptoms and signs
Measured: from date of randomization until failure reported for up to 100 months
Secondary outcomes (1)
Radiographic success
treatment could be further evaluated based on absence of canal oblitration
Measured: from date of randomization until failure reported for up to 100 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Jun 2017
- Study start4 Jul 2013
- Primary completion1 Dec 2020 (estimated)
- Study completion4 Oct 2023 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Deep CariesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- This prospective longitudinal, parallel-design, randomized clinical trial was set up and is reported according to CONSORT statement
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 60 participants (actual)
Sponsor and investigators
- Lead sponsor
- Jordan University of Science and Technology
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Lama Awawdeh, PhD, Study chair, Jordan University of Science and Technology
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03186690
- Sponsor's protocol ID
- 154/2013
- Status last verified
- Sep 2019
- First submitted
- 27 May 2017
- Last updated
- 25 Sep 2019
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 25 Sep 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- 154/2013 Grant for Mineral Trioxide Aggregate and Biodentine for Vital Pulp Therapy
- ClinicalTrials.gov ID
- NCT03186690
- Acronym / sponsor ID
- 154/2013
- Conditions
- Deep Caries, Reversible Pulpitis, Irreversible Pulpitis
- Keywords
- vital pulp therapy, Biodentine, Mineral Trioxide Aggregate
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 60 participants (actual)
- Lead sponsor
- Jordan University of Science and TechnologyUniversity, hospital or other
- Study start
- 4 Jul 2013 (actual)
- Primary completion
- 1 Dec 2020 (estimated)
- Study completion
- 4 Oct 2023 (estimated)
- First posted
- 14 Jun 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aimed to evaluate the clinical performance of White MTA (MTA, Angelus, Londrina, Brazil) and Biodentine™ in pulp capping of cariously exposed mature permanent teeth.
The investigator performed a prospective longitudinal randomized controlled study utilizing vital permanent mature teeth with deep caries. Patients will be divided randomly into Biodentine™ and MTA groups; Teeth will be assessed clinically and radiographically prior to the procedure. Caries will be excavated under local anesthesia, hemostasis is achieved after pulp exposure using NaOCl and will be capped with Biodentine™ or MTA. Clinical and radiographical follow-up will be performed by a blinded calibrated evaluator after six months and one year, and yearly after.
Detailed description
Study design and ethical approval This prospective longitudinal, parallel-design, randomized clinical trial was set up and is reported according to CONSORT statement. It assessed the outcome of using Biodentine or MTA as a capping material in human mature permanent teeth. Ethical approval for this study was obtained from the Institution Review Board (IRB number (154/13). All participants provided written informed consent after the purpose and methodology were explained in full.
Patient recruitment All patients visiting the Initial Treatment Unit and Post Graduate Dental Clinics were screened for inclusion . Dental examinations were performed to determine whether the patients fulfilled the needed criteria
Approximately 50 subjects will be needed for the study in order to elicit any significant findings as demonstrated by a power analysis from a similar study. The patients will be divided into two groups based on the capping material used. Biodentine™ (Septodont, St. Maur-des-Fossés, France) group, and MTA reparative cement (Angelus, Londrina, Brazil) group. Teeth will be randomly assigned to either group with a coin toss. This included patients with a single offending tooth; the following patient will be then assigned to the other group to keep sample sizes equal in both groups. Patients with more than one offending tooth will have one tooth treated with Biodentine and the other with MTA using again coin toss to randomly distribute capping material among offending teeth.
Clinical examination Pre-operative clinical examinations included a visual inspection of the extent of caries, gingival health, and adjacent soft tissue. A percussion test will be performed, and the periodontal status will be assessed. Pulpal sensibility will also be assessed by cold test with Endo Ice F (Colten-Whaledent, Germany). Patients reporting sharp pain to cold test that did not linger were diagnosed with reversible pulpitis. Patients reporting severe lingering or spontaneous pain were diagnosed with irreversible pulpitis.
Periapical and bitewing radiographs will be obtained for each offending tooth to assess the extent and location of caries, proximity of caries to the pulp, restorability of each tooth, periapical status, and presence of intra-radicular pathosis. Radiographs will be taken using a parallel technique and will be viewed by the naked eye using a viewing box with uniform bright light in a darkened room. All data will be collected by one examiner to ensure reliability.
Clinical protocol Profound local anesthesia of each tooth will achieved by standard infiltration or inferior dental block injection with lidocaine and epinephrine (1:100000) (Xylestesin-A 3M ESPE, Seefeld, Germany). Then, the tooth will be isolated with a rubber dam. The clinical crown disinfected with a cotton pellet soaked in chlorhexidine. Caries will be excavated using a round, high-speed diamond bur with adequate water cooling followed by a round carbide bur. Every attempt will be carried to remove all carious tissue before exposing the pulp. A cotton pellet moistened with 5% NaOCl to be placed into the cavity before pulpal exposure. The size of the pellet varied according to the size of remaining caries; The moistened cotton pellet was left in place for 1-5 minutes to achieve hemostasis. Sodium hypochlorite-soaked cotton will be used to control bleeding in this study.
Once bleeding stopped, capping material will be placed over the exposed pulp. Failure to stop bleeding within additional 3 minutes indicated incomplete removal of the inflamed pulp. In these cases, partial or complete pulpotomy will be performed before capping. Failure to control bleeding after a full pulpotomy indicated propagation of the inflammation to the radicular pulp.
Biodentine™ will be prepared according to the manufacturer's instructions and used to fill half the cavity. Biodentine™ should set within 12 minutes according to the manufacturer. MTA reparative cement will be prepared at a powder:liquid ratio of 3:1 using distilled water according to manufacturer's instructions . MTA to be applied to exposed pulp tissue and adjacent dentine at a thickness of 1.5 to 3 mm. The final restoration will be a resin composite (Z250, 3M, ESPE, USA). Patients are asked to contact the operator if they experience any pain. The first review appointment to be scheduled a week after capping procedure. The patient will be questioned about sensitivity, mastication discomfort, and sensations of pain.
Recall protocol Six-month and yearly after follow-up appointments will be scheduled. Patients, who are not aware of the type of capping material received, will be questioned about pain, sensitivity, and mastication discomfort. Clinical examinations to be performed to detect soft tissue swelling, sinus tract, the integrity of the coronal restoration, and tooth mobility. The review visits to be performed blindly by another operator. Radiographical examinations will also be performed to evaluate the periapical status, the formation of the dentine bridge, pulpal calcifications, or canal obliteration and evidence of tooth discoloration. Tooth vitality will be monitored by cold tests. Treatment was considered successful based on the following features: absence of severe spontaneous pain, no discomfort while eating, no soft tissue swelling, mobility that is no greater than grade I, the absence of periapical rarefaction, internal or external resorption, root canal obliteration, and normal viability following pulpotomy.
Statistical analysis The data will be processed using the JMP software (SAS Institute Inc., North Carolina, United States) with alpha=0.05. The chi-square test (significance level of < 0.05) will be used to determine differences between the success rates of Biodentine and MTA. The survival probabilities will be compared using The Wilcoxon and the log-rank tests.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
- Model description
- This prospective longitudinal, parallel-design, randomized clinical trial was set up and is reported according to CONSORT statement
| Arm | Type | Receives |
|---|---|---|
| Biodentine | Experimental | Other: BiodentineThis includes teeth that were treated with Biodntine cement |
| Mineral Trioxide Aggregate | Experimental | Other: Mineral Trioxide AggregateThis includes teeth that were treated with Mineral Trioxide Aggregate (MTA) cement |
Who may qualify
- Ages
- 16 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (7 listed)
- Teeth that Fulfilled All the Following Criteria Were Selected
- Vital teeth responding positively to cold test.
- Reversible or irreversible pulpitis with or without periapical lesion.
- Deep caries that if removed exposure of the pulp is most likely to occur.
- Permanent mature molar, premolar or anterior tooth
Key exclusion criteria (4 listed)
- Immature tooth
- Unrestorable tooth
- Tooth that did not respond to cold test
- Serious medical problem that could prevent the patient from receiving the treatment or attending later the follow up visits.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Biodentine | Other | Biodentine |
| Mineral Trioxide AggregateAlso: MTA | Other | Mineral Trioxide Aggregate |
Primary outcome
clinical vital pulp therapy success
Time frame: from date of randomization until failure reported for up to 100 months
Treatment was considered successful based on absence of symptoms and signs
1 secondary outcome
Radiographic success
Time frame: from date of randomization until failure reported for up to 100 months
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Sep 2019.
- Individual participant dataSharing planned: No
Related trials for Deep Caries
RecruitingPhase 2
Clinical and Radiographic Success Rate of Pulpotomy Versus Pulpectomy for Management of Primary Teeth With Deep Caries
Deep Caries
Recruiting
"The Relationship Between Pulpal Inflammatory Marker Levels in Moderate and Severe Pulpitis and Outcome of Full Pulpotomy in Mandibular Molars With Extremely Deep Caries: A Prospective Cohort Study."
Moderate Severe Pulpitis, Extremely Deep Caries
Recruiting
Outcome of Partial Pulpotomy in Permanent Mandibular Molars With Symptomatic Irreversible Pulpitis After Wound Lavage With Calcium Hypochlorite or Sodium Hypochlorite
Symptomatic Irreversible Pulpitis (SIP), Extremely Deep Caries
Active, not recruiting
Outcome of Selective Caries Removal Performed by Undergraduate Students
Deep Caries Lesion of Pemanent Teeth
Active, not recruiting
Direct Pulp Capping Compared to Partial Pulpotomy in Carious Pulp Exposures
Deep Caries
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Lama Awawdeh, PhD study chair
Jordan University of Science and Technology
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Biodentine and Mineral Trioxide Aggregate in people with Deep Caries and Reversible Pulpitis, run by Jordan University of Science and Technology at 1 site in Jordan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 25 Sep 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Jordan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
clinical vital pulp therapy success (time frame: from date of randomization until failure reported for up to 100 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Sep 2019; AzTrials last refreshed its copy on 6 Nov 2026.